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Introduction {#sec004}
============

Leptospirosis is a worldwide zoonotic disease recognized as an important emerging infectious disease in the past few decades. This disease occurs in diverse epidemiological settings, especially in tropical or subtropical regions of the world but imparts the greatest burden on resource-limited populations \[[@pntd.0008074.ref001]\]. Leptospirosis was estimated to cause a million cases and close to 60,000 deaths annually \[[@pntd.0008074.ref002]\]. Leptospirosis affects risk groups that are exposed to animal reservoirs or contaminated environments but exerts a broader health impact on impoverished farmers from the tropical regions \[[@pntd.0008074.ref003]\]. This disease has also emerged as a health threat in new settings due to the influence of globalization and climate change, where natural disasters and extreme weather events are now recognized to precipitate epidemics \[[@pntd.0008074.ref004], [@pntd.0008074.ref005]\].

This disease is caused by spirochetes belonging to the genus *Leptospira*, comprising of both saprophytic and pathogenic species. The clinical manifestations of human leptospirosis are diverse, ranging from mild, flu-like illness to a more severe form of the disease known as Weil's syndrome, which is characterized by jaundice, acute renal and hepatic failure, pulmonary distress, and hemorrhage, which can lead to death. These symptoms are similar to those of other infectious diseases, such as dengue fever and malaria, often causing misdiagnosis. Early diagnosis of this disease is crucial because antibiotic therapy provides the greatest benefit and is the most efficacious when initiated early in the course of an illness \[[@pntd.0008074.ref003]\].

Dark-field microscopy is a conventional method for leptospirosis diagnosis through direct microscopic observation of clinical specimens. However, the sensitivity of this method is low, and the result is affected by the timing of sample collection and the skill of laboratory personnel \[[@pntd.0008074.ref001]\]. *Leptospira* can be isolated from clinical specimens through inoculation into an appropriate culture medium, but its application in the field is hampered by the long doubling time and the need for special media in addition to its low sensitivity \[[@pntd.0008074.ref006]\]. Microscopic agglutination test (MAT) is the current reference standard serological diagnostic test in leptospirosis. However, MAT requires the maintenance of live leptospires. As a minimum, the panel of live leptospires should include all locally circulating serovars; otherwise, an incomplete panel could lead to a false negative result \[[@pntd.0008074.ref007]\]. Therefore, although MAT is considered as the gold standard test for leptospirosis diagnosis, it is laborious and its requirement for a large panel of live *Leptospira* culture hinders its standardization \[[@pntd.0008074.ref008]\]. Other serological tests also have been developed with the likes of ELISA, complement fixation, indirect hemagglutination, latex bead agglutination, and indirect immunofluorescence \[[@pntd.0008074.ref001], [@pntd.0008074.ref003], [@pntd.0008074.ref009]\], but all have been hampered by their low sensitivities for the initial management of acute leptospirosis \[[@pntd.0008074.ref008]\].

These drawbacks have led to the increased development and use of nucleic acid-based diagnostics, such as conventional and real-time polymerase chain reaction (PCR) and isothermal amplification methods, which feature high sensitivity \[[@pntd.0008074.ref010]\]. The advantage of nucleic acid-based diagnostics lies in their ability to obtain a definitive diagnosis during the acute stage of the disease even before antibodies are detectable \[[@pntd.0008074.ref008]\]. Hence, these methods tend to replace the serological methods in endemic zones. They are normally based on the detection of a certain gene present in *Leptospira*. Genes such as *rrs*, *secY*, *lipL32*, *flaB*, *lfb1*, *ligA*, and *ligB2* have all been used as targets of nucleic acid-based diagnosis \[[@pntd.0008074.ref011]--[@pntd.0008074.ref014]\] and have been detected from blood, urine, cerebrospinal fluid, and tissue samples \[[@pntd.0008074.ref015]\].

However, little is known about the diagnostic accuracy of each genetic marker. In addition, most studies had a low number of samples, which limited the statistical power and scientific reliability of the results. This meta-analysis was conducted to pool and analyze simultaneously all studies that used nucleic acid techniques to detect *Leptospira* in clinical samples of humans and animals. This pooled analysis aimed to provide a precise estimation of the diagnostic accuracy of nucleic acid techniques to detect *Leptospira*.

Methods {#sec005}
=======

Literature search {#sec006}
-----------------

A systematic review of nucleic acid techniques in detecting *Leptospira* was conducted based on the principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements ([S1 Checklist](#pntd.0008074.s001){ref-type="supplementary-material"}).

### Data sources {#sec007}

Relevant studies were identified by systematic search of electronic databases Scopus, PubMed, MEDLINE (from 1946 until present; via Ovid). and non-indexed citations (via Ovid).

### Search strategy {#sec008}

The search of relevant studies was carried out up to December 2018 by using subject headings and free text terms. The search was carried out with the keywords "(leptospirosis OR leptospira\*) AND (human OR patient OR animal OR clinical) AND (sensitivity OR specificity OR "true positive" OR "true negative" OR "false positive" OR "false negative")".

Inclusion criteria {#sec009}
------------------

Cross-sectional and cohort studies that assessed nucleic acid techniques for the detection of *Leptospira* in human or animal clinical samples against at least one reference test were included, regardless of publication year. Laboratory diagnoses of leptospirosis are usually based on several methods or a combination of these methods due to the temporal nature of the disease progression and the absence of a satisfactory universal reference test \[[@pntd.0008074.ref008]\]. Studies with reference tests such as MAT, any PCR-based tests, isolation of leptospires through culture, or the detection of antibodies to the bacteria, were considered for inclusion. Studies must directly or indirectly provide at least four values, which are number of true positives (TPs), false positives (FPs), true negatives (TNs), and false negatives (FNs), to construct or reconstruct a two-by-two table. Only articles published in English were evaluated.

Exclusion criteria {#sec010}
------------------

The relevance of each study was determined based on their types. Reviews that do not contain original data and proceedings that did not employ any peer-review process were excluded. In addition, letters, editorials, and case reports were excluded. The objectives and methods were assessed, and studies were excluded if (1) samples were not tested by at least one reference test; (2) they involved spiked samples; (3) they involved experimentally infected animals; (4) data to derive a two-by-two table were insufficient; and (5) multiple genes were targeted in the index test.

Data abstraction {#sec011}
----------------

### Study selection {#sec012}

The titles and abstracts of potentially relevant studies from the literature search were screened by one reviewer in accordance with the eligibility criteria and further confirmed by a second reviewer. After the exclusion of duplicated records, studies without abstract, and apparently irrelevant studies, the full-text articles of remaining studies were screened by two reviewers. Disagreements about study inclusion and exclusion were resolved between the reviewers by consensus.

### Data extraction and quality assessment {#sec013}

Data were extracted primarily by one reviewer and cross-checked by a second reviewer. Data collected from eligible studies included the first author name, publication year, characteristics of study population, number of samples, type of samples, type of method used as index test and reference test, and number of TPs, FPs, TNs, and FNs. Any disagreements between the two reviewers were documented and resolved through discussion with a third reviewer.

Data analysis {#sec014}
-------------

The extracted data were compiled in a summary table, and the numbers of TPs, FPs, TNs, and FNs were used to calculate the sensitivity and specificity in each study. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were determined for each group. For each statistic, the corresponding 95% confidence intervals (95% CI) were also calculated. The DOR is a single measure of diagnostic test performance that describes the odds of having a positive result in participants with a positive reference test compared against the odds in those with a negative reference test \[[@pntd.0008074.ref016]\]. The DORs were evaluated using the DerSimonian-Laird method (random effects model) \[[@pntd.0008074.ref017]\]. Summary receiver operating characteristic (SROC) curves that show the relationship between sensitivity and false positives rate (1 --specificity) were constructed to summarize the results. The area under the curve (AUC) of the SROC was calculated and proposed as a means to assess diagnostic data in the context of meta-analysis \[[@pntd.0008074.ref018]\].

Heterogeneity was assessed by using *I*^2^ statistics and was interpreted as follows: an *I*^2^ value of less than 50% indicates homogeneity among the studies in the analysis, whereas an *I*^2^ value of more than 50% represents substantial heterogeneity among the studies \[[@pntd.0008074.ref019]\]. One of the causes for heterogeneity observed in the meta-analysis of diagnostics is the threshold effect, which occurs if the studies use different thresholds to define a positive test result. In the present analysis, the presence of the threshold effect was determined by calculating the Spearman correlation coefficient between the sensitivity and specificity of the included studies \[[@pntd.0008074.ref020]\]. In the absence of the threshold effect, meta-regression and subgroup analyses were performed to explore the contribution of individual factors on the heterogeneity observed, where a *p* value of less than 0.05 indicates a contribution to heterogeneity. All statistical analyses were carried out using Meta-DiSc software (version 1.4) \[[@pntd.0008074.ref021]\].

Results {#sec015}
=======

Literature search and study characteristics {#sec016}
-------------------------------------------

The study selection process is presented in [Fig 1](#pntd.0008074.g001){ref-type="fig"}. The search for literature was completed in December 2018 and identified 1645 records, of which 128 full-text articles were retrieved to assess for eligibility. Of these full-text articles, 86 were excluded after further scrutiny. Forty-two studies involving 7414 samples met the inclusion criteria and were included in the meta-analysis. Detail and characteristics of each included study are presented in [Table 1](#pntd.0008074.t001){ref-type="table"}. The studies included were conducted in different countries and were published from 1992 to 2018. Some of the included studies used different methods; thus, the data were reported as separate independent studies \[[@pntd.0008074.ref012], [@pntd.0008074.ref022]--[@pntd.0008074.ref032]\].

![Flow chart of study selection process.](pntd.0008074.g001){#pntd.0008074.g001}

10.1371/journal.pntd.0008074.t001

###### Characteristics of studies included in the meta-analysis.

![](pntd.0008074.t001){#pntd.0008074.t001g}

  Study                        Country                                                                                                   Study population                                                                                          Number of samples                         Sample type                             Index test                             Gene target              Reference test                              TP   FP   FN    TN
  ---------------------------- --------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------- --------------------------------------- -------------------------------------- ------------------------ ------------------------------------------- ---- ---- ----- -----
  \[[@pntd.0008074.ref010]\]   Brazil                                                                                                    Suspected leptospirosis patients                                                                          478                                       Human---DNA from serum                  Taqman qRT-PCR                         *rrs*                    MAT                                         3    32   30    413
  \[[@pntd.0008074.ref011]\]   Netherlands                                                                                               Suspected leptospirosis patients                                                                          133                                       Human---DNA from serum or blood         SYBR Green qPCR                        *secY*                   Culture                                     15   8    0     110
  \[[@pntd.0008074.ref012]\]   Pacific Islands                                                                                           Suspected leptospirosis patients                                                                          51                                        Human---DNA from serum                  SYBR Green qPCR                        *lfb1*                   MAT                                         12   13   6     20
  Pacific Islands              Suspected leptospirosis patients                                                                          51                                                                                                        Human---DNA from serum                    Nested PCR                              *rrs*                                  MAT                      12                                          13   6    20    
  \[[@pntd.0008074.ref022]\]   Sri Lanka                                                                                                 Febrile patients                                                                                          105                                       Human---DNA from blood                  Taqman qPCR                            *rrs*                    MAT                                         9    1    40    55
  Sri Lanka                    Febrile patients                                                                                          105                                                                                                       Human---DNA from serum                    Taqman qPCR                             *rrs*                                  MAT                      25                                          1    24   55    
  \[[@pntd.0008074.ref023]\]   Brazil                                                                                                    Suspected leptospirosis patients                                                                          521                                       Human---DNA from serum                  Conventional PCR                       *rrs*                    MAT                                         4    0    24    493
  Brazil                       Suspected leptospirosis patients                                                                          521                                                                                                       Human---DNA from serum                    Nested PCR                              *rrs*                                  MAT                      24                                          0    4    493   
  \[[@pntd.0008074.ref024]\]   Brazil                                                                                                    Clinically confirmed leptospirosis patients, patients of other febrile diseases and healthy individuals   77                                        Human---DNA from blood or urine         Conventional PCR                       LP1                      MAT                                         11   0    22    44
  Brazil                       Clinically confirmed leptospirosis patients, patients of other febrile diseases and healthy individuals   77                                                                                                        Human---DNA from blood or urine           Conventional PCR                        *secY*                                 MAT                      19                                          0    14   44    
  \[[@pntd.0008074.ref025]\]   NR                                                                                                        Stray and household cats (healthy, non-vaccinated)                                                        63                                        Animal---DNA from serum or urine        LAMP                                   *lipL32*                 Taqman qPCR (*lipL32*)                      22   0    2     39
  NR                           Stray and household cats (healthy, non-vaccinated)                                                        63                                                                                                        Animal---DNA from serum or urine          Nested PCR                              *lipL32*                               Taqman qPCR (*lipL32*)   17                                          3    7    36    
  NR                           Stray and household cats (healthy, non-vaccinated)                                                        63                                                                                                        Animal---DNA from serum or urine          Conventional PCR                        *rrs*                                  Taqman qPCR (*lipL32*)   1                                           0    23   39    
  NR                           Stray and household cats (healthy, non-vaccinated)                                                        63                                                                                                        Animal---DNA from serum or urine          Conventional PCR                        *secY*                                 Taqman qPCR (*lipL32*)   3                                           0    21   39    
  \[[@pntd.0008074.ref026]\]   Philippines                                                                                               Clinically confirmed leptospirosis patients                                                               113                                       Human---DNA from urine pellet           SYBR Green qPCR                        *flaB*                   MAT                                         3    4    74    32
  Philippines                  Clinically confirmed leptospirosis patients                                                               113                                                                                                       Human---DNA from plasma or urine pellet   LAMP                                    *rrs*                                  MAT                      2                                           3    75   33    
  \[[@pntd.0008074.ref027]\]   Japan                                                                                                     Stray rats                                                                                                18                                        Animal---Boiled urine sample            Nested PCR                             *flaB*                   Culture                                     6    0    6     6
  Japan                        Stray rats                                                                                                16                                                                                                        Animal---Urine pellet sample              Nested PCR                              *flaB*                                 Culture                  9                                           1    2    4     
  Japan                        Stray rats                                                                                                18                                                                                                        Animal---Boiled urine sample              LAMP                                    *rrs*                                  Culture                  11                                          2    1    4     
  Japan                        Stray rats                                                                                                16                                                                                                        Animal---Urine pellet sample              LAMP                                    *rrs*                                  Culture                  10                                          2    1    3     
  \[[@pntd.0008074.ref028]\]   Thailand                                                                                                  Clinically confirmed leptospirosis patients                                                               266                                       Human---DNA from blood                  LAMP                                   *lipL41*                 Culture, MAT                                50   13   83    120
  Thailand                     Clinically confirmed leptospirosis patients                                                               266                                                                                                       Human---DNA from blood                    LAMP                                    *rrs*                                  Culture, MAT             58                                          22   75   111   
  \[[@pntd.0008074.ref029]\]   Brazil                                                                                                    Suspected leptospirosis patients                                                                          332                                       Human---DNA from serum                  Taqman qPCR                            *lipL32*                 Culture, MAT                                37   3    90    202
  Brazil                       Suspected leptospirosis patients                                                                          332                                                                                                       Human---DNA from whole blood              Taqman qPCR                             *lipL32*                               Culture, MAT             77                                          12   50   193   
  \[[@pntd.0008074.ref030]\]   Thailand                                                                                                  Febrile patients                                                                                          266                                       Human---DNA from blood                  Taqman qPCR                            *lipL32*                 Culture, MAT                                57   9    76    124
  Thailand                     Febrile patients                                                                                          266                                                                                                       Human---DNA from blood                    Taqman qPCR                             *rrs*                                  Culture, MAT             74                                          14   59   119   
  \[[@pntd.0008074.ref031]\]   Argentina                                                                                                 Clinically confirmed leptospirosis patients and non-cases                                                 234                                       Human---DNA from serum or blood         Conventional PCR                       *lipL32*                 Culture, MAT                                26   2    81    125
  Argentina                    Clinically confirmed leptospirosis patients and non-cases                                                 234                                                                                                       Human---DNA from serum or blood           Taqman qPCR                             *lipL32*                               Culture, MAT             47                                          9    60   118   
  \[[@pntd.0008074.ref032]\]   Denmark                                                                                                   Suspected leptospirosis patients                                                                          51                                        Human---DNA from urine                  Taqman qPCR                            *lipL32*                 MAT                                         3    1    0     47
  Denmark                      Suspected leptospirosis patients                                                                          51                                                                                                        Human---DNA from urine                    Taqman qPCR                             *rrs*                                  MAT                      3                                           1    0    47    
  \[[@pntd.0008074.ref033]\]   Sri Lanka                                                                                                 Suspected leptospirosis patients                                                                          40                                        Human---DNA from serum                  Taqman qPCR                            *rrs*                    MAT                                         5    5    11    19
  \[[@pntd.0008074.ref034]\]   NR                                                                                                        Suspected leptospirosis patients                                                                          63                                        Human---DNA from serum or blood         Recombinase polymerase amplification   *lipL32*                 Culture                                     18   1    1     43
  \[[@pntd.0008074.ref035]\]   Brazil                                                                                                    Suspected leptospirosis patients                                                                          46                                        Human---RNA from blood                  Taqman qRT-PCR                         *rrs*                    Culture, MAT, qPCR                          14   0    8     24
  \[[@pntd.0008074.ref036]\]   Sri Lanka                                                                                                 Suspected leptospirosis patients                                                                          170                                       Human---DNA from blood                  Nested PCR                             *rrs*                    MAT                                         7    7    54    102
  \[[@pntd.0008074.ref037]\]   Thailand                                                                                                  Febrile patients                                                                                          418                                       Human---DNA from blood                  Nested PCR                             *rrs*                    Culture                                     37   81   2     298
  \[[@pntd.0008074.ref038]\]   Barbados                                                                                                  Post-mortem samples                                                                                       13                                        Human---DNA from organ                  Conventional PCR                       *secY*                   Culture, MAT                                2    0    6     5
  \[[@pntd.0008074.ref039]\]   USA                                                                                                       Random                                                                                                    34                                        Animal---Urine pellet sample            Conventional PCR                       IS1500                   MAT                                         23   3    7     1
  \[[@pntd.0008074.ref040]\]   Czech Republic                                                                                            Suspected leptospirosis patients                                                                          852                                       Human---DNA from plasma, urine or CSF   Conventional PCR                       *secY*                   MAT                                         14   1    21    816
  \[[@pntd.0008074.ref041]\]   Sri Lanka                                                                                                 Suspected leptospirosis patients                                                                          95                                        Human---DNA from blood                  SYBR Green qPCR                        *secY*                   MAT                                         44   3    21    27
  \[[@pntd.0008074.ref042]\]   Uruguay                                                                                                   Suspected leptospirosis patients                                                                          183                                       Human---DNA from serum                  SYBR Green qPCR                        *lipL32*                 MAT                                         26   0    59    98
  \[[@pntd.0008074.ref043]\]   Turkey                                                                                                    Suspected leptospirosis patients and animals                                                              133                                       Human and animal---DNA from serum       Nested PCR                             *rrs*                    MAT                                         90   2    0     41
  \[[@pntd.0008074.ref044]\]   NR                                                                                                        Suspected leptospirosis dogs                                                                              135                                       Animal---DNA from serum                 Nested PCR                             *rrs*                    MAT                                         47   23   4     61
  \[[@pntd.0008074.ref045]\]   Thailand                                                                                                  Wild rodents                                                                                              36                                        Animal---DNA from kidney                Taqman qPCR                            *lipL32*                 Conventional PCR (*gyrB*)                   4    0    0     32
  \[[@pntd.0008074.ref046]\]   NR                                                                                                        Suspected leptospirosis patients and healthy controls                                                     28                                        Human---DNA from urine, CSF or blood    Conventional PCR                       *rrs*                    MAT                                         4    0    2     22
  \[[@pntd.0008074.ref047]\]   Malaysia                                                                                                  Suspected leptospirosis patients                                                                          65                                        Human---DNA from blood                  Taqman qPCR                            *rrs*                    Commercial GenoAmp qPCR leptospirosis kit   10   1    0     54
  \[[@pntd.0008074.ref048]\]   India                                                                                                     Suspected leptospirosis patients                                                                          207                                       Human---DNA from serum                  Taqman qPCR                            *lipL32*                 MAT                                         84   10   77    36
  \[[@pntd.0008074.ref049]\]   India                                                                                                     Suspected leptospirosis patients                                                                          134                                       Human---NR                              Conventional PCR                       *secY*                   MAT                                         34   4    1     95
  \[[@pntd.0008074.ref050]\]   NR                                                                                                        Suspected leptospirosis patients                                                                          42                                        Human---DNA from blood or urine         Conventional PCR                       *flaB*                   MAT                                         39   0    0     3
  \[[@pntd.0008074.ref051]\]   Brazil                                                                                                    Suspected leptospirosis patients                                                                          92                                        Human---DNA from serum                  Conventional PCR                       *secY*                   MAT                                         17   13   30    32
  \[[@pntd.0008074.ref052]\]   India                                                                                                     Suspected leptospirosis patients                                                                          207                                       Human---DNA from blood                  Nested PCR                             *lipL32*                 Culture                                     21   3    79    104
  \[[@pntd.0008074.ref053]\]   Nicaragua                                                                                                 Febrile patients                                                                                          85                                        Human---DNA from blood                  Taqman qPCR                            *lipL32*                 MAT                                         11   6    27    41
  \[[@pntd.0008074.ref054]\]   Brazil                                                                                                    Patients with meningeal abnormalities                                                                     39                                        Human---DNA from CSF                    Conventional PCR                       *rrs*                    MAT                                         10   13   2     14
  \[[@pntd.0008074.ref055]\]   India                                                                                                     Suspected leptospirosis patients                                                                          100                                       Human---DNA from serum                  Conventional PCR                       *rrs*                    MAT                                         2    4    16    78
  \[[@pntd.0008074.ref056]\]   India                                                                                                     Asymptomatic participants                                                                                 196                                       Human---DNA from urine                  Taqman qPCR                            *rrs*                    MAT                                         37   67   22    70
  \[[@pntd.0008074.ref057]\]   NR                                                                                                        Suspected leptospirosis patients                                                                          231                                       Human---DNA from serum or blood         Taqman qPCR                            *rrs*                    Culture                                     27   1    1     202
  \[[@pntd.0008074.ref058]\]   NR                                                                                                        Wild animals                                                                                              220                                       Animal---DNA from serum                 Taqman qPCR                            *rrs*                    MAT                                         0    1    14    205
  \[[@pntd.0008074.ref059]\]   Brazil                                                                                                    Suspected leptospirosis patients                                                                          55                                        Human---DNA from serum or plasma        Taqman qRT-PCR                         *rrs*                    MAT                                         6    47   0     2
  \[[@pntd.0008074.ref060]\]   Laos                                                                                                      Febrile patients                                                                                          787                                       Human---DNA from blood or urine         Taqman qPCR                            *rrs*                    Culture, MAT                                7    69   26    685

NR represents information not reported

Accuracy of nucleic acid techniques targeting the *rrs* gene {#sec017}
------------------------------------------------------------

The pooled sensitivity of techniques targeting the *rrs* gene was 0.51 (95% CI: 0.48--0.54), whereas the pooled specificity was 0.90 (95% CI: 0.89--0.91). [Fig 2](#pntd.0008074.g002){ref-type="fig"} shows the detailed forest plot of the sensitivities and specificities of the included studies. The pooled DOR was 13.58 (95% CI: 6.66--27.67), as shown in [Fig 3](#pntd.0008074.g003){ref-type="fig"}. [Fig 4](#pntd.0008074.g004){ref-type="fig"} shows the SROC curve; the AUC and the pooled diagnostic accuracy (Q\*) were 0.88 and 0.81, respectively. Significant heterogeneity was observed among the studies (sensitivity, *I*^2^ = 95.3%; specificity, *I*^2^ = 96.6%; DOR, *I*^2^ = 84.0%).

![Forest plots of sensitivity and specificity of studies using *rrs* as the target gene for the detection of *Leptospira*.](pntd.0008074.g002){#pntd.0008074.g002}

![Forest plot of DOR of targeting the *rrs* gene in the detection of *Leptospira*.](pntd.0008074.g003){#pntd.0008074.g003}

![SROC curve of targeting the *rrs* gene in the detection of *Leptospira*.](pntd.0008074.g004){#pntd.0008074.g004}

The Spearman correlation coefficient was calculated to be 0.273 with *p* = 0.160 (\> 0.05), indicating that the significant heterogeneity was not due to the threshold effect. Hence meta-regression and subgroup analyses were performed to explore the overall heterogeneity and identify the source of heterogeneity, including the type of index test and type of sample (human or animal). The meta-regression analysis did not demonstrate that these two covariates contributed to the heterogeneity (*p* \> 0.05 for both covariates). Subgroup analyses were performed on the basis of these covariates, and the results are shown in [Table 2](#pntd.0008074.t002){ref-type="table"}. Only one study dealt with human and animal samples; thus, analysis was not performed for this sample category.

10.1371/journal.pntd.0008074.t002

###### Meta-analysis results of studies targeting the *rrs* gene for the detection of *Leptospira*.

![](pntd.0008074.t002){#pntd.0008074.t002g}

                                      Sensitivity (95% CI)   Specificity (95% CI)   PLR (95% CI)         NLR (95% CI)        DOR (95% CI)           AUC
  ----------------------------------- ---------------------- ---------------------- -------------------- ------------------- ---------------------- ------
  **All studies**                     0.51 (0.48--0.54)      0.90 (0.89--0.91)      4.36 (2.80--6.79)    0.56 (0.44--0.70)   13.58 (6.66--27.67)    0.88
  **Subgroup (Type of index test)**                                                                                                                 
  **Conventional PCR**                0.24 (0.15--0.34)      0.97 (0.96--0.98)      7.09 (1.27--39.72)   0.86 (0.70--1.05)   11.61 (2.43--55.45)    0.78
  **Nested PCR**                      0.76 (0.70--0.80)      0.89 (0.87--0.91)      4.62 (2.32--9.21)    0.13 (0.01--2.20)   53.18 (6.83--413.92)   0.95
  **qPCR**                            0.50 (0.45--0.55)      0.90 (0.89--0.92)      8.14 (3.00--22.09)   0.62 (0.42--0.90)   17.21 (5.19--57.05)    0.92
  **qRT-PCR**                         0.38 (0.26--0.51)      0.85 (0.81--0.88)      2.82 (0.15--53.67)   0.68 (0.23--2.04)   3.80 (0.21--67.78)     0.68
  **LAMP**                            0.35 (0.29--0.41)      0.84 (0.78--0.89)      2.01 (1.04--3.91)    0.64 (0.34--1.18)   3.57 (0.70--18.23)     0.83
  **Subgroup (Type of sample)**                                                                                                                     
  **Human samples**                   0.44 (0.41--0.48)      0.90 (0.89--0.91)      4.45 (2.67--7.40)    0.61 (0.49--0.77)   11.09 (5.17--23.79)    0.83
  **Animal samples**                  0.62 (0.52--0.71)      0.92 (0.88--0.94)      3.22 (2.34--4.45)    0.39 (0.17--0.92)   20.90 (8.55--51.08)    0.89

Accuracy of nucleic acid techniques targeting the *lipL32* gene {#sec018}
---------------------------------------------------------------

The pooled sensitivity and specificity of techniques using the *lipL32* gene as the target of detection were 0.42 (95% CI: 0.39--0.46) and 0.95 (95% CI: 0.94--0.97), respectively. The detailed forest plots of the sensitivities and specificities of the included studies are shown in [Fig 5](#pntd.0008074.g005){ref-type="fig"}. The pooled DOR was 19.71 (95% CI: 10.15--38.29), as shown in [Fig 6](#pntd.0008074.g006){ref-type="fig"}. The SROC curve is presented in [Fig 7](#pntd.0008074.g007){ref-type="fig"} with an AUC of 0.92 and Q\* value of 0.85. Significant heterogeneity was observed among the studies (sensitivity, *I*^2^ = 91.1%; specificity, *I*^2^ = 75.9%; DOR, *I*^2^ = 72.4%).

![Forest plots of sensitivity and specificity of studies using *lipL32* as the target gene for the detection of *Leptospira*.](pntd.0008074.g005){#pntd.0008074.g005}

![Forest plot of DOR of targeting the *lipL32* gene in the detection of *Leptospira*.](pntd.0008074.g006){#pntd.0008074.g006}

![SROC curve of targeting the *lipL32* gene in the detection of *Leptospira*.](pntd.0008074.g007){#pntd.0008074.g007}

The Spearman correlation coefficient was -0.077 with *p* = 0.794 (\> 0.05), indicating that significant heterogeneity was not due to the threshold effect. Meta-regression and subgroup analyses were then performed to explore the heterogeneity and identify the source of heterogeneity. The meta-regression analysis did not demonstrate that the two covariates (type of index test and type of sample) contributed to the heterogeneity (*p* \> 0.05 for both). Subgroup analyses were performed on the basis of these covariates, and the results are shown in [Table 3](#pntd.0008074.t003){ref-type="table"}. The AUC for the subgroup of index test (nested PCR) was not computed because of the low number of studies (n = 2). Analysis for the following index tests could not be performed because only one study was present in each category: conventional PCR, LAMP, and recombinase polymerase amplification.

10.1371/journal.pntd.0008074.t003

###### Meta-analysis results of studies targeting the *lipL32* gene for the detection of *Leptospira*.
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                                      Sensitivity (95% CI)   Specificity (95% CI)   PLR (95% CI)         NLR (95% CI)        DOR (95% CI)           AUC
  ----------------------------------- ---------------------- ---------------------- -------------------- ------------------- ---------------------- ------
  **All studies**                     0.42 (0.39--0.46)      0.95 (0.94--0.97)      9.42 (5.64--15.75)   0.61 (0.51--0.71)   19.71 (10.15--38.29)   0.92
  **Subgroup (Type of index test)**                                                                                                                 
  **Nested PCR**                      0.31 (0.23--0.40)      0.96 (0.91--0.98)      8.35 (3.71--18.79)   0.52 (0.17--1.65)   15.31 (4.93--47.52)    NA
  **qPCR**                            0.44 (0.41--0.48)      0.95 (0.93--0.96)      7.83 (4.21--14.56)   0.62 (0.54--0.72)   13.64 (6.52--28.54)    0.75
  **Subgroup (Type of sample)**                                                                                                                     
  **Human samples**                   0.40 (0.37--0.44)      0.95 (0.94--0.96)      8.33 (4.82--14.37)   0.65 (0.57--0.75)   14.65 (7.57--28.32)    0.86

Accuracy of nucleic acid techniques targeting the *secY* gene {#sec019}
-------------------------------------------------------------

[Fig 8](#pntd.0008074.g008){ref-type="fig"} shows the forest plots of the sensitivities and specificities of techniques targeting the *secY* gene. The pooled sensitivity and specificity were 0.56 (95% CI: 0.50--0.63) and 0.98 (95% CI: 0.97--0.98), respectively. The pooled DOR was valued at 46.16 (95% CI: 6.20--343.49) and is presented in [Fig 9](#pntd.0008074.g009){ref-type="fig"}. [Fig 10](#pntd.0008074.g010){ref-type="fig"} shows the SROC curve with the AUC at 0.94 and the pooled diagnostic accuracy (Q\*) at 0.88. Among these studies, significant heterogeneity was observed (sensitivity, *I*^2^ = 92.0%; specificity, *I*^2^ = 92.4%; DOR, *I*^2^ = 88.3%).
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The Spearman correlation coefficient was 0.000 with *p* = 1.000 (\> 0.05), indicating that the heterogeneity was not due to the threshold effect. Thus, meta-regression and subgroup analyses were performed to explore the source of heterogeneity. The meta-regression analysis did not demonstrate that the two covariates contributed to the heterogeneity (*p* \> 0.05 for both covariates). Subgroup analyses based on these covariates were performed, and the results are shown in [Table 4](#pntd.0008074.t004){ref-type="table"}. The AUC for the subgroup of index test (qPCR) was not determined because of the low number of studies (n = 2). Analysis for animal samples was not performed because only one study was present in this category.

10.1371/journal.pntd.0008074.t004

###### Meta-analysis results of studies targeting the *secY* gene for the detection of *Leptospira*.
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                                      Sensitivity (95% CI)   Specificity (95% CI)   PLR (95% CI)           NLR (95% CI)        DOR (95% CI)            AUC
  ----------------------------------- ---------------------- ---------------------- ---------------------- ------------------- ----------------------- ------
  **All studies**                     0.56 (0.50--0.63)      0.98 (0.97--0.98)      12.94 (3.74--44.72)    0.49 (0.30--0.82)   46.16 (6.20--343.49)    0.94
  **Subgroup (Type of index test)**                                                                                                                    
  **Conventional PCR**                0.49 (0.41--0.56)      0.98 (0.97--0.99)      15.63 (2.04--119.78)   0.60 (0.37--0.97)   39.57 (2.44--642.05)    0.91
  **qPCR**                            0.74 (0.63--0.83)      0.93 (0.87--0.96)      10.50 (4.65--23.71)    0.13 (0.00--6.15)   65.78 (3.37--1284.84)   NA
  **Subgroup (Type of index test)**                                                                                                                    
  **Human samples**                   0.61 (0.54--0.67)      0.97 (0.96--0.98)      13.17 (3.52--49.33)    0.45 (0.27--0.77)   54.70 (5.97--501.49)    0.94

Accuracy of nucleic acid techniques targeting the *flaB* gene {#sec020}
-------------------------------------------------------------

For techniques targeting the *flaB* gene, the pooled sensitivity and specificity of the included studies were 0.41 (95% CI: 0.33--0.50) and 0.90 (95% CI: 0.78--0.97), respectively. The forest plots of the sensitivities and specificities are shown in [Fig 11](#pntd.0008074.g011){ref-type="fig"}. The pooled DOR was 10.42 (95% CI: 0.44--244.84), as shown in [Fig 12](#pntd.0008074.g012){ref-type="fig"}. The SROC curve is presented in [Fig 13](#pntd.0008074.g013){ref-type="fig"}, with the AUC at 0.92 and pooled diagnostic accuracy (Q\*) at 0.86. Significant heterogeneity was observed when computing the pooled sensitivity (*I*^2^ = 97.8%) and DOR (*I*^2^ = 82.1%).
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The Spearman correlation coefficient was 0.600 with *p* = 0.400 (\> 0.05), eliminating the possibility of the threshold effect. The meta-regression analysis did not demonstrate that the two covariates contributed to the heterogeneity (*p* \> 0.05 for both covariates). Subgroup analyses were not performed because of the limited number of studies in each subgroup.

Discussion {#sec021}
==========

In this meta-analysis, 42 studies involving 7414 samples were included to investigate the diagnostic accuracy of various nucleic acid techniques. Many nucleic acid diagnostics for leptospirosis have been developed and designed to either target housekeeping genes that are common to all species of *Leptospira* or pathogenic species-specific genes. Here, from the literature searched, we pooled and analyzed the diagnostic performance of nucleic acid assays targeting the *rrs*, *lipL32*, *secY* and *flaB* genes. The IS1500, LP1, *lfb1*, and *lipL41* genes were not pooled and analyzed because only one study included each of these genes \[[@pntd.0008074.ref012], [@pntd.0008074.ref024], [@pntd.0008074.ref028], [@pntd.0008074.ref039]\].

The *rrs* gene is a housekeeping gene found ubiquitously among leptospires. The present meta-analysis showed that assays targeting the *rrs* gene have been well-established and largely used for diagnostics. Targeting the *rrs* gene can allow the detection of pathogenic or saprophytic *Leptospira* species \[[@pntd.0008074.ref059]\]. The *rrs* gene is also present in two copies per *Leptospira*, which could consequently increase its chance of being amplified \[[@pntd.0008074.ref061], [@pntd.0008074.ref062]\]. Meanwhile, the *secY* gene encodes for preprotein translocase for *Leptospira* and is located within the S10-spc-α locus containing genes for ribosomal proteins \[[@pntd.0008074.ref063]\]. Similar to the *rrs* gene, it is a housekeeping gene that is also common to all leptospires \[[@pntd.0008074.ref011]\]. The *secY* gene consists of alternating conserved and variable regions, making it suitable to design primers that can generate amplicons across the *Leptospira* genus and enable phylogenetic interpretation through the variable regions \[[@pntd.0008074.ref064]\].

The *lipL32* gene encodes a major lipoprotein located in the outer membrane of leptospires. The *lipL32* gene is present in all species from both pathogenic and intermediate strains but absent in saprophytic strains, suggesting its critical role in infection \[[@pntd.0008074.ref065], [@pntd.0008074.ref066]\]. The sequence of the *lipL32* gene is highly conserved across the pathogenic species of *Leptospira*, with more than 94% amino acid sequence identities \[[@pntd.0008074.ref067]\]. Thus, the absence of *lipL32* in saprophytic *Leptospira* makes it a specific and appropriate gene target for diagnosing leptospirosis \[[@pntd.0008074.ref025]\]. Another gene that can be used to differentiate between pathogenic and saprophytic leptospires is the *flaB* gene. This gene encodes for flagellin, a class B polypeptide subunit of the periplasmic flagella. The sequence of *flaB* is also highly conserved among pathogenic serovars of *Leptospira* \[[@pntd.0008074.ref068]\]. Similar to the *lipL32* gene, the absence of *flaB* in the saprophytic strains allows this gene to be a good target for detecting pathogenic leptospires \[[@pntd.0008074.ref050], [@pntd.0008074.ref069]\].

As shown in [Table 5](#pntd.0008074.t005){ref-type="table"}, nucleic acid techniques targeting the *secY* gene exhibited better pooled sensitivity and specificity when compared against assays targeting the *rrs*, *lipL32*, or *flaB* gene. Sensitivity and specificity are true performance statistics of the test, where sensitivity measures for the proportion of samples tested positive among those tested positive using a reference test while specificity measures the proportion of samples tested negative among those tested negative in a reference test \[[@pntd.0008074.ref070]\]. The PLR of assays targeting *secY* is also the highest among others and is the only one with a value more than 10. This result indicates that the positive results obtained from assays targeting *secY* are useful for the confirmation of leptospirosis \[[@pntd.0008074.ref071]\]. Sensitivity and specificity play important roles in determining the DOR of a test. For example, tests with high sensitivity and specificity with low FPs and FNs result in a high DOR \[[@pntd.0008074.ref016]\]. In our analysis, the pooled DOR of assays targeting *secY* was the highest among other genes. Collectively, the pooled sensitivity, specificity, DOR, likelihood ratio, and AUC data all support that assays targeting the *secY* gene are highly discriminatory for the detection of *Leptospira*.

10.1371/journal.pntd.0008074.t005

###### Summary of diagnostic accuracy measures of genetic markers for the detection of *Leptospira* in clinical samples.
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  Gene           Sensitivity (95% CI)   Specificity (95% CI)   PLR (95% CI)          NLR (95% CI)        DOR (95% CI)           AUC
  -------------- ---------------------- ---------------------- --------------------- ------------------- ---------------------- ------
  ***rrs***      0.51 (0.48--0.54)      0.90 (0.89--0.91)      4.36 (2.80--6.79)     0.56 (0.44--0.70)   13.58 (6.66--27.67)    0.88
  ***lipL32***   0.42 (0.39--0.46)      0.95 (0.94--0.97)      9.42 (5.64--15.75)    0.61 (0.51--0.71)   19.71 (10.15--38.29)   0.92
  ***secY***     0.56 (0.50--0.63)      0.98 (0.97--0.98)      12.94 (3.74--44.72)   0.49 (0.30--0.82)   46.16 (6.20--343.49)   0.94
  ***flaB***     0.41 (0.33--0.50)      0.90 (0.78--0.97)      2.43 (0.44--13.52)    0.36 (0.11--1.18)   10.42 (0.44--244.84)   0.92

Stratified analyses were performed for each gene analyzed according to the type of index test. For the *rrs* gene, subgroup analysis revealed that nested PCR assays targeting the gene are superior over other tests and slightly better than qPCR, as exhibited by the higher DOR and AUC of the SROC curve. In a previous study, qRT-PCR assay targeting the *rrs* gene was compared against nested PCR assay of the same gene, and the diagnostic performance was comparable between the two \[[@pntd.0008074.ref072]\]. Another study on the detection of *Strongyloides stercoralis* also found that nested PCR shows better diagnostic sensitivity than real-time PCR \[[@pntd.0008074.ref073]\]. However superior nested PCR is, real-time PCR methods are usually preferred over the former because they provide an accurate diagnosis faster than nested PCR assays \[[@pntd.0008074.ref074]\]. By contrast, qPCR assay targeting the *lipL32* gene showed slightly better performance than nested PCR assay, but this finding is inconclusive because AUC data for nested PCR assay was not computed due to the lack of studies. As for the *secY* gene, although AUC data for qPCR were not determined, the sensitivity and DOR of qPCR were significantly higher than those of conventional PCR. When the data were stratified according to the type of samples, assays targeting the *rrs* gene showed slightly better diagnostic performance on animal than human samples. Meanwhile, the diagnostic performance of the other genes on animal samples was not computed because of the lack of studies. As for human samples, assays targeting the *secY* gene showed the best diagnostic performance in terms of DOR, followed by those targeting *lipL32*, *rrs*, and *flaB*.

However, the findings of this meta-analysis should be interpreted with caution, considering the significant unexplained heterogeneity. The heterogeneity of the analyzed studies could be due to the vastly different sample sizes among the included studies. Moreover, the low number of studies in assays targeting the *flaB* gene and in some subgroups might have also biased the results. Another possible contribution to the heterogeneity of the studies was the variability in the DNA sample extraction approach, reference test, and the stage of the disease when samples were collected from the patients and animals. The timing of sample collection is crucial for the detection of *Leptospira* DNA because it is present in the blood of the patient in the first 5 to 10 days after the onset of the disease \[[@pntd.0008074.ref011]\]. As mentioned previously, although MAT has been the gold standard for the diagnosis of leptospirosis, its application is limited by its difficulty to be standardized \[[@pntd.0008074.ref008]\], suggesting that this limitation also contributed to the heterogeneity observed. In these nucleic acid assays, the different targeting regions within each gene would represent a major factor influencing the sensitivity and specificity of a diagnostic test. These limitations could have negatively influenced the overall results of this work.

In short, current evidence suggests that the *secY* gene has better diagnostic accuracy measures with *lipL32*, *flaB*, and *rrs* coming close as promising genetic markers for leptospirosis diagnosis. However, the high degree of heterogeneity observed in this meta-analysis mitigates any conclusions drawn from the combined data. Nevertheless, future studies evaluating the nucleic acid-based diagnostic assays should consider the timing and stage of the disease for sample collection, the choice of reference test to be compared with, or the statistical methods to optimize the imperfect reference tests, in an effort to reduce the heterogeneity between the studies while increasing the comparability of results.
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